Highlights Adastra Holdings Ltd.

Equities

XTRX

CA00654D1006

Market Closed - Canadian Securities Exchange Other stock markets 13:47:23 2024-05-15 EDT			5-day change	1st Jan Change
0.18 ^CAD	-7.69%		-12.20%	-18.18%

04-24	Adastra Holdings Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
04-15	Adastra Holdings Ltd. Announces Appointment of Lachlan Mcleod as Interim Chief Executive Officer	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Adastra Holdings Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	04-23	CI
Adastra Holdings Ltd. Announces Record Total Purchase Orders Received in January and February	03-14	CI
Adastra Holdings Ltd. Receives Purchase Order from the Alberta Gaming, Liquor & Cannabis	03-01	CI
Adastra Holdings Brief: Announcing it has received a Purchase Order for C$1,047,439 from Alberta Gaming, Liquor & Cannabis	03-01	MT
XORTX Therapeutics Brief: Says Submitted a New Patent for the Treatment of Chronic Kidney Disease	01-03	MT
Adastra Holdings Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-29	CI
Adastra Holdings Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-17	CI
XORTX Therapeutics Announces PKD Presentation	23-06-06	MT
Adastra Holdings Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-31	CI
Adastra Holdings Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-30	CI
Adastra Brief: Says To Defend Lawsuit Alleging Co "Misstated Certain Material Facts"; Currently, No Specific Amount of Damages Is Claimed"	23-03-15	MT
Adastra Labs "Clarifies and Retracts" Certain Disclosure Related to its Receipt of Health Canada Approval for Amendment to Include Cocaine Under its Controlled Substances Licence	23-03-03	MT
Adastra Labs Receives Health Canada OK for Amendment to Include Cocaine Under its Controlled Substances Dealer's License	23-02-22	MT
Adastra Labs Receives Health Canada Approval for the Amendment to Include Cocaine Under its Controlled Substances Dealer’s License	23-02-22	CI
Adastra Completes Transaction to Terminate Legacy Supply Agreement, Bringing Phyto Extractions Brand 100% In-House	23-02-15	CI
Adastra Holdings Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-29	CI
XORTX Therapeutics Brief: Announced Over Weekend Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency	22-11-28	MT
Adastra Holdings Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-26	CI
XORTX Therapeutics Announces Positive Topline Results From Pharmacokinetics Bridging Clinical Trial	22-07-13	MT
XORTX Therapeutics Brief: Announcing Positive Topline Results from Pharmacokinetics Bridging Clinical Trial	22-07-13	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Adastra Holdings Ltd.

Equities

XTRX

CA00654D1006

Highlights

Filters